Drugs / Zosuquidar
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00233909 | Oct 2005 → Mar 2008 | myeloid leukemia | Kanisa Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT00129168 | Aug 2005 → Mar 2008 | myeloid leukemia | Kanisa Pharmaceuticals | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT00046930 | Sep 2002 → Jun 2009 | myelodysplastic syndrome, myeloid leukemia | Eastern Cooperative Oncology Group | Completed | Missed primary |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zosuquidar | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00046930 ↗ |
| Known as | NSC-725086 | ChEMBL registry synonym — accepted as the source's own label CHEMBL444172 ↗ |
| Known as | Zos | “PURPOSE: To evaluate the safety, tolerability, pharmacodynamics (PD), and potential efficacy of zosuquidar (Zos) in combination with daunorubicin and cytarabine in elderly...” PMID 38407601 ↗ Feb 20241“zosuquidar (Zos) in combination with gemtuzumab ozogamicin (GO)” PMID 37603048 ↗ Aug 2023 |
| Known as | zosuquidar trihydrochloride | “Drug: zosuquidar trihydrochloride” NCT00046930 ↗ |
| Action | Inhibit | “90-95% inhibition of blast P-gp function during Zos infusion” PMID 37603048 ↗ Aug 20231“P-glycoprotein 1 inhibitor” CHEMBL444172 ↗ |
| Modality | Small molecule | — CHEMBL444172 ↗ |
| Route | Intravenous | “Zosuquidar 550 mg/day by continuous intravenous infusion” NCT00046930 ↗ |
| Target | ABCB1 | “P-glycoprotein 1 inhibitor” CHEMBL444172 ↗ |